PhaseBio Suitor Gets $2M Breakup Fee Without Ch. 11 Auction

An Italian pharmaceutical company chosen to serve as a bidder-to-beat for a later-canceled Delaware Chapter 11 auction of drug research firm PhaseBio Pharmaceuticals still deserves a $2 million breakup fee based...

Already a subscriber? Click here to view full article